Comparative Pharmacology
Head-to-head clinical analysis: INDIUM IN 111 OXYQUINOLINE versus MPI DMSA KIDNEY REAGENT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: INDIUM IN 111 OXYQUINOLINE versus MPI DMSA KIDNEY REAGENT.
INDIUM IN 111 OXYQUINOLINE vs MPI DMSA KIDNEY REAGENT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Indium In 111 oxyquinoline is a radiolabeled compound that chelates indium-111 with oxyquinoline. The lipophilic complex penetrates cell membranes and binds to intracellular components, primarily in leukocytes (neutrophils). After intravenous injection, the radiolabeled cells accumulate at sites of inflammation or infection, allowing gamma camera imaging to detect focal areas of abnormal leukocyte localization.
DMSA (dimercaptosuccinic acid) labeled with technetium-99m binds to renal cortex, particularly proximal tubular cells, allowing scintigraphic imaging of functional renal parenchyma. Uptake correlates with renal blood flow and tubular function.
1-2 mCi (37-74 MBq) labeled autologous leukocytes, administered intravenously over 1-2 minutes.
Adults: 74-185 MBq (2-5 mCi) intravenously, single dose for renal imaging.
None Documented
None Documented
Terminal elimination half-life is approximately 4-6 hours for the free indium ion, but biological half-life for labeled cells can be 1-2 days depending on cell type.
Initial whole-body half-life of dimer captosuccinic acid (DMSA) is 1.1 hours; terminal elimination half-life for cortical retention is 56 days, reflecting prolonged renal tubular uptake.
Renal excretion approximately 70-80% within 24 hours; fecal excretion less than 5%.
Renal: ~50% excreted unchanged in urine within 24 hours; remaining fraction retained in renal tubular cells with gradual release over weeks.
Category C
Category C
Radiopharmaceutical
Radiopharmaceutical